Market revenue in 2023 | USD 37,823.0 million |
Market revenue in 2030 | USD 66,064.5 million |
Growth rate | 8.3% (CAGR from 2023 to 2030) |
Largest segment | Anti-vegf agents |
Fastest growing segment | Gene & Cell Therapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti-Allergy, Anti-VEGF agents, Anti-inflammatory, Anti-glaucoma, Gene & Cell Therapy |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
anti-vegf agents was the largest segment with a revenue share of 32.71% in 2023. Horizon Databook has segmented the Global ophthalmic drugs market based on anti-allergy, anti-vegf agents, anti-inflammatory, anti-glaucoma, gene & cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global ophthalmic drugs market , including forecasts for subscribers. This global databook contains high-level insights into Global ophthalmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account